Across TCGA pan-cancer cohorts, APOLD1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated APOLD1 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher APOLD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated APOLD1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
UCEC, LUAD, and SKCM are the cancer types where APOLD1 Mutation most reproducibly stratifies survival.